Health

BioAtla Announces Share Consolidation

March 31, 2026 16:06 ET  | Source: BioAtla, Inc. SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:…

20 hours ago

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – –…

20 hours ago

NextCure and Simceres SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 March 31, 2026…

20 hours ago

Alvotech files Annual Report with the SEC

REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for…

2 days ago

Alvotech Publishes 2025 Annual Report

REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is…

2 days ago

MemoryON Claims Evaluated: Hidden Details Emerge About Memory On Brain Support Supplementation for Memory Loss

Aurora, CO, March 30, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through these…

2 days ago

Medical AI Named First-Ever Recipient of ACC Global Digital Health Award at American College of Cardiology Annual Scientific Session

NEW ORLEANS, March 29, 2026 (GLOBE NEWSWIRE) -- Medical AI, a company specializing in artificial intelligence-enabled electrocardiogram (ECG) solutions for…

2 days ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue…

2 days ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

March 28, 2026 15:00 ET  | Source: Roivant Sciences The results of the Phase 3 VALOR trial were published in…

2 days ago

Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%

“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage…

3 days ago